240‐week entecavir maleate treatment in Chinese chronic hepatitis B predominantly genotype B or C

This study aimed to evaluate the efficacy and safety of entecavir(ETV) versus ETV maleate in Chinese patients with chronic hepatitis B(CHB). This was a randomized, double‐blind, double‐dummy, controlled, multicentre study. Patients were randomly assigned to receive 48 weeks of treatment with 0.5 mg/...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Jing‐Hang, Fan, Ya‐Nan, Yu, Yan‐Yan, Si, Chong‐Wen, Zeng, Zheng, Xu, Zhong‐Nan, Li, Jun, Mao, Qing, Zhang, Da‐Zhi, Tang, Hong, Sheng, Ji‐Fang, Chen, Xin‐Yue, Ning, Qin, Shi, Guang‐Feng, Xie, Qing, Zhang, Xi‐Quan, Dai, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9545224/
https://www.ncbi.nlm.nih.gov/pubmed/35737855
http://dx.doi.org/10.1111/jvh.13724

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9545224/
https://www.ncbi.nlm.nih.gov/pubmed/35737855
http://dx.doi.org/10.1111/jvh.13724

Ejemplares similares